San FranciscoFounded 20247+ employeesPrivate
$7.6M raisedSeed· last: seed (Jul 2024)· 2 rounds
Backed by(19 investors)
Granza Bio is developing programmable therapeutics for the immune system. Our platform is built on the foundational discovery of immune “superkiller” attack particles — the natural ammunition used by cytotoxic immune cells to deliver potent, localized killing. By re-arming exhausted immune cells with newly programmed ammunition, Granza restores and enhances immune function. This approach enables a new class of treatments with the potential to transform diseases ranging from cancer to autoimmunity.
